Innate Immunotherapeutics Limited (ASX Code:IIL) has today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 March 2017.
The cash balance as at 31 March 2017 was $5,763,000, a decrease of $253,000 from the end of the previous quarter.
Net cash usage for the three months was $2,403,000. Of this amount, $1,769,000 related to research and development, being principally the Company's Phase 2B trial of MIS416 in patients with secondary progressive multiple sclerosis (SPMS) together with the MIS416 manufacturing industrialisation project.
For further information please download PDF attached:
Download this document
